With insitro deal, Gilead turns to machine learning to unlock new NASH targets

Not yet content with the trio of clinical programs in its pipeline, Gilead has struck its third NASH deal this year, this time banking on machine learning company insitro to develop disease models and discover targets for non-alcoholic steatohepatitis.

Making its first biopharma deal since launching last year, insitro Inc. (Menlo Park, Calif.) was founded by machine learning veteran Daphne Koller, the company's CEO. She told BioCentury that the partners will feed data sets from NASH clinical trials conducted by Gilead Sciences Inc. (NASDAQ:GILD) into the insitro Human (ISH) platform to generate in vitro models and identify targets. Koller said that the platform combines machine learning, human genetics and functional genomics, and is designed to be predictive of clinical outcomes...